CXCR1 and breast carcinoma: Reparixin is an investigational, non-competitive allosteric inhibitor of the IL-8 receptors CXCR1 and CXCR2 [24] and it has been investigated as a potential novel antineoplastic agent in synergy with standard chemotherapy targeting the CXCR1+ breast cancer stem population [25–27].